Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development
暂无分享,去创建一个
M. Karsdal | C. Christiansen | E. Dam | K. Duffin | P. Qvist | O. Nemirovskiy | K. Henriksen | N. Barascuk | L. Klickstein | D. Leeming | P. Aggarwal | I. Byrjalsen | M. Karsdal | A. Bay-Jensen | P. Mitchell | D. Leeming | A. Bay‐Jensen | C. Christiansen | S. Madsen
[1] M. Karsdal,et al. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. , 2009, Osteoarthritis and cartilage.
[2] M. Hellio le Graverand,et al. Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis. , 2008, Osteoarthritis and cartilage.
[3] O. Nemirovskiy,et al. Immunoaffinity liquid chromatography-tandem mass spectrometry detection of nitrotyrosine in biological fluids: development of a clinically translatable biomarker. , 2008, Analytical biochemistry.
[4] Claus Christiansen,et al. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? , 2008, Pharmacological research.
[5] Claus Christiansen,et al. Automatic quantification of local and global articular cartilage surface curvature: Biomarkers for osteoarthritis? , 2008, Magnetic resonance in medicine.
[6] K Henriksen,et al. Should subchondral bone turnover be targeted when treating osteoarthritis? , 2008, Osteoarthritis and cartilage.
[7] C. Christiansen,et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. , 2008, Osteoarthritis and cartilage.
[8] E. Vignon,et al. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. , 2008, Clinical and experimental rheumatology.
[9] H. Jick,et al. Use of thiazolidinediones and fracture risk. , 2008, Archives of internal medicine.
[10] M. Karsdal,et al. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality , 2008, Osteoporosis International.
[11] Gillian Murphy,et al. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? , 2008, Nature Clinical Practice Rheumatology.
[12] M. Karsdal,et al. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies , 2008, Osteoporosis International.
[13] M. Karsdal,et al. Osteoclasts secrete non-bone derived signals that induce bone formation. , 2008, Biochemical and biophysical research communications.
[14] M. Karsdal,et al. Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[15] Claus Christiansen,et al. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity , 2008, Arthritis research & therapy.
[16] M. Karsdal,et al. 64 CARTILAGE LONGEVITY: A PROGNOSTIC OA BIOMARKER COMBINING BIOCHEMICAL AND MRI-BASED CARTILAGE MARKERS , 2007 .
[17] T. Spector,et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study , 2007, Arthritis research & therapy.
[18] M. Karsdal,et al. Diphyllin, a Novel and Naturally Potent V‐ATPase Inhibitor, Abrogates Acidification of the Osteoclastic Resorption Lacunae and Bone Resorption , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] M. Karsdal,et al. Separation of healthy and early osteoarthritis by automatic quantification of cartilage homogeneity. , 2007, Osteoarthritis and cartilage.
[20] E. Wooltorton,et al. Diabetes drug pioglitazone (Actos): risk of fracture , 2007, Canadian Medical Association Journal.
[21] B. Bresnihan,et al. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. , 2007, Arthritis and rheumatism.
[22] A. C. Yazici,et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. , 2007, The Journal of clinical endocrinology and metabolism.
[23] P. Pettersen,et al. Automatic morphometric cartilage quantification in the medial tibial plateau from MRI for osteoarthritis grading. , 2007, Osteoarthritis and cartilage.
[24] P. Delmas,et al. Biological markers in osteoarthritis , 2007, Nature Clinical Practice Rheumatology.
[25] A. Bailey,et al. Bone, not cartilage, should be the major focus in osteoarthritis , 2007, Nature Clinical Practice Rheumatology.
[26] S. Cummings,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[27] M. Karsdal,et al. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. , 2007, Arthritis and rheumatism.
[28] Claus Christiansen,et al. Are Nonresorbing Osteoclasts Sources of Bone Anabolic Activity? , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] Claus Christiansen,et al. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases , 2007, Osteoporosis International.
[30] R. Short. Fracture risk a class effect of thiazolidinediones in women , 2007, British medical journal.
[31] M. Karsdal,et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. , 2007, Osteoarthritis and cartilage.
[32] M. Karsdal,et al. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. , 2007, Osteoarthritis and cartilage.
[33] O. Nemirovskiy,et al. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. , 2007, Analytical biochemistry.
[34] M. Karsdal,et al. Osteoclasts prefer aged bone , 2007, Osteoporosis International.
[35] M. Karsdal,et al. Biochemical markers in preclinical models of osteoporosis , 2007, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[36] S. Cummings,et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.
[37] M. Karsdal,et al. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood , 2006, Journal of Bone and Mineral Metabolism.
[38] E. Roos,et al. Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis , 2006, BMC musculoskeletal disorders.
[39] R. Buck,et al. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. , 2006, Osteoarthritis and cartilage.
[40] T. Spector,et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. , 2006, Arthritis and rheumatism.
[41] E. Thonar,et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. , 2006, Arthritis and rheumatism.
[42] L. Tankó,et al. Early elevation in circulating levels of C-telopeptides of type II collagen predicts structural damage in articular cartilage in the rodent model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.
[43] M. Karsdal,et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice , 2006, European Journal of Clinical Pharmacology.
[44] M. Karsdal,et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. , 2006, Osteoarthritis and cartilage.
[45] M. Karsdal,et al. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. , 2006, Osteoarthritis and cartilage.
[46] Claus Christiansen,et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. , 2006, Arthritis and rheumatism.
[47] D J Hunter,et al. Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.
[48] C. Bingham,et al. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. , 2006, Rheumatology.
[49] M. Karsdal,et al. Alpha CTX as a Biomarker of Skeletal Invasion of Breast Cancer: Immunolocalization and the Load Dependency of Urinary Excretion , 2006, Cancer Epidemiology Biomarkers & Prevention.
[50] M. Karsdal,et al. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. , 2006, Osteoarthritis and cartilage.
[51] P. Delmas,et al. Bone quality--the material and structural basis of bone strength and fragility. , 2006, The New England journal of medicine.
[52] L. Tankó,et al. The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients , 2006, Cancer Epidemiology Biomarkers & Prevention.
[53] L. Tankó,et al. Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[54] K. Park,et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. , 2005, Endocrine journal.
[55] M. Karsdal,et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? , 2005, Assay and drug development technologies.
[56] M. Karsdal,et al. Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo. , 2005, The American journal of pathology.
[57] M. Karsdal,et al. The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment. , 2005, Drug news & perspectives.
[58] M. Karsdal,et al. Degradation of the Organic Phase of Bone by Osteoclasts: A Secondary Role for Lysosomal Acidification , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[59] M. Karsdal,et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. , 2005, Bone.
[60] A. Bailey,et al. Enzymic and non‐enzymic cross‐linking mechanisms in relation to turnover of collagen: relevance to aging and exercise , 2005, Scandinavian journal of medicine & science in sports.
[61] A. Silman,et al. Predictive Value of BMD for Hip and Other Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[62] C. Little,et al. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. , 2005, Arthritis and rheumatism.
[63] C. Little,et al. Matrix Metalloproteinases Are Not Essential for Aggrecan Turnover during Normal Skeletal Growth and Development , 2005, Molecular and Cellular Biology.
[64] A. Fourie,et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro , 2005, Nature.
[65] H. Ma,et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis , 2005, Nature.
[66] T. Spector,et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173] , 2005, Arthritis research & therapy.
[67] Andrea Messori,et al. New drugs for rheumatoid arthritis [6] (multiple letters) , 2004 .
[68] R. Recker,et al. Bone Remodeling Increases Substantially in the Years After Menopause and Remains Increased in Older Osteoporosis Patients , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[69] C. Christiansen,et al. Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology‐Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3‐Month Effects on Biomarkers of Bone Turnover , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[70] C. Christiansen,et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM) , 2004, Menopause.
[71] A. Uitterlinden,et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. , 2004, Arthritis and rheumatism.
[72] M. C. Ovejero,et al. The Chloride Channel Inhibitor NS3736 Prevents Bone Resorption in Ovariectomized Rats Without Changing Bone Formation , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[73] A. Dorner,et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. , 2004, Matrix biology : journal of the International Society for Matrix Biology.
[74] E. Vignon,et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. , 2004, Osteoarthritis and cartilage.
[75] M. Karsdal,et al. Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. , 2004, The American journal of pathology.
[76] J. Pelletier,et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. , 2004, Bone.
[77] L. Tankó,et al. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application , 2004, Arthritis research & therapy.
[78] M. Inaba,et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline , 2004, Journal of Bone and Mineral Metabolism.
[79] J. Reginster,et al. Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[80] A. Rowan,et al. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. , 2003, Arthritis and rheumatism.
[81] Kim Henriksen,et al. Transforming Growth Factor-β Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression* , 2003, Journal of Biological Chemistry.
[82] Alexander Fraser,et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. , 2003, Arthritis and rheumatism.
[83] M. Mathieu,et al. Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. , 2003, The Journal of clinical endocrinology and metabolism.
[84] G. Duyk. Attrition and Translation , 2003, Science.
[85] J. Krupa,et al. Use of anti-neoepitope antibodies for the analysis of degradative events in cartilage and the molecular basis for neoepitope specificity. , 2003, Biochemical Society symposium.
[86] D. Mercer,et al. Identification, expression, and tissue distribution of the three rat lysyl hydroxylase isoforms. , 2003, Biochemical and biophysical research communications.
[87] R. Hargreaves,et al. Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.
[88] C. Christiansen,et al. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. , 2003, Bone.
[89] M. Karsdal,et al. The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen Degradation , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[90] B. Månsson,et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept , 2003, Arthritis research & therapy.
[91] C. Christiansen,et al. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index , 2003, Annals of the rheumatic diseases.
[92] David F. Horrobin,et al. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.
[93] John A. Wagner,et al. Overview of Biomarkers and Surrogate Endpoints in Drug Development , 2002, Disease markers.
[94] C. Lathia. Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development? , 2002, Disease markers.
[95] M. Dougados,et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. , 2002, Arthritis and rheumatism.
[96] M. Hyttinen,et al. Transgenic mouse models for studying the role of cartilage macromolecules in osteoarthritis. , 2002, Rheumatology.
[97] G. Guyatt,et al. VI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis , 2002 .
[98] G. Guyatt,et al. III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis , 2002 .
[99] W. B. Berg. Lessons from animal models of arthritis , 2002 .
[100] P. Delmas,et al. Type I Collagen Racemization and Isomerization and the Risk of Fracture in Postmenopausal Women: The OFELY Prospective Study , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[101] D. Edwards,et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. , 2002, Arthritis and rheumatism.
[102] Fran Harris,et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.
[103] P. Qvist,et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. , 2001, Bone.
[104] C. Christiansen,et al. Bone Resorption in Post-menopausal Women with Normal and Low BMD Assessed with Biochemical Markers Specific for Telopeptide Derived Degradation Products of Collagen Type I , 2001, Calcified Tissue International.
[105] S. Kondo,et al. Cytokine regulation of cartilage‐derived retinoic acid‐sensitive protein (CD‐RAP) in primary articular chondrocytes: suppression by IL‐1, bfGF, TGFβ and stimulation by IGF‐1 , 2001, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[106] D. Kiel,et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.
[107] T. Martin,et al. Therapeutic approaches to bone diseases. , 2000, Science.
[108] P. Sexton,et al. Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. , 2000, The Journal of endocrinology.
[109] S. Mohan,et al. Development and Application of a Serum C-Telopeptide and Osteocalcin Assay to Measure Bone Turnover in an Ovariectomized Rat Model , 2000, Calcified Tissue International.
[110] P. Alexandersen,et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. , 2000, Bone.
[111] P. Sambrook,et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. , 2000, The Journal of clinical endocrinology and metabolism.
[112] J. Risteli,et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. , 2000, Bone.
[113] B. Gelb,et al. Determination of Bone Markers in Pycnodysostosis: Effects of Cathepsin K Deficiency on Bone Matrix Degradation , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[114] J. Martel-Pelletier,et al. Cytokines and their role in the pathophysiology of osteoarthritis. , 1999, Frontiers in bioscience : a journal and virtual library.
[115] G D Roodman,et al. Cell biology of the osteoclast. , 1999, Experimental Hematology.
[116] A. Hollander,et al. Denaturation of type II collagen in articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible cartilage damage , 1999, The Journal of pathology.
[117] C. Christiansen,et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. , 1999, The Journal of clinical endocrinology and metabolism.
[118] J. V. van Meurs,et al. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. , 1999, Arthritis and rheumatism.
[119] C. Christiansen,et al. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. , 1999, Bone.
[120] H. Weinstein,et al. Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. , 1999, The Journal of clinical investigation.
[121] C. Wijmenga,et al. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[122] S. Robins,et al. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation. , 1999, Clinical science.
[123] R. G. Paul,et al. Mechanisms of maturation and ageing of collagen , 1998, Mechanisms of Ageing and Development.
[124] C. Christiansen,et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. , 1998, Clinical chemistry.
[125] C. Christiansen,et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. , 1998, Clinical chemistry.
[126] R. Parker,et al. Early Changes in Biochemical Markers of Bone Turnover Predict the Long‐Term Response to Alendronate Therapy in Representative Elderly Women: A Randomized Clinical Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[127] C. Christiansen,et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. , 1998, The New England journal of medicine.
[128] C. Rosen,et al. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. , 1997, The Journal of clinical endocrinology and metabolism.
[129] P. Qvist,et al. Characterization of Urinary Degradation Products Derived from Type I Collagen , 1997, The Journal of Biological Chemistry.
[130] C Marcelli,et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[131] J. Pelletier,et al. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. , 1996, The Journal of clinical investigation.
[132] H. Oxlund,et al. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. , 1995, Bone.
[133] C. Christiansen,et al. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. , 1995, The Journal of clinical endocrinology and metabolism.
[134] P. Dieppe,et al. Biological markers in rheumatoid arthritis. , 1994, Seminars in arthritis and rheumatism.
[135] D. Heinegård,et al. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. , 1994, Annals of the rheumatic diseases.
[136] W. O'Fallon,et al. Long‐term fracture prediction by bone mineral assessed at different skeletal sites , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[137] D. Heinegård,et al. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. , 1992, British journal of rheumatology.
[138] V. Monnier,et al. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. , 1989, The Journal of biological chemistry.
[139] J. Pelletier,et al. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. , 1989, The Journal of clinical investigation.
[140] T. Oegema,et al. Biochemical changes in articular cartilage after joint immobilization by casting or external fixation , 1989, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[141] C. Christiansen,et al. NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSIS , 1989, Clinical endocrinology.
[142] L. Avioli,et al. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. , 1988, The Journal of clinical investigation.
[143] A J Bailey,et al. Isolation and structural identification of a labile intermolecular crosslink in collagen. , 1968, Biochemical and biophysical research communications.
[144] J. Kellgren,et al. Radiological Assessment of Osteo-Arthrosis , 1957, Annals of the rheumatic diseases.
[145] S. Berney,et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis , 2008 .
[146] M. Karsdal,et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. , 2007, Bone.
[147] R. Short. Fracture risk is a class effect of glitazones. , 2007, British medical journal.
[148] Ole Fogh Olsen,et al. Segmenting Articular Cartilage Automatically Using a Voxel Classification Approach , 2007, IEEE Transactions on Medical Imaging.
[149] M. Karsdal,et al. Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression? , 2006, Drugs.
[150] Y. Yazici,et al. Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.
[151] M. Karsdal,et al. Molecular Pathogenesis of Genetic and Inherited Diseases Acidification of the Osteoclastic Resorption Compartment Provides Insight into the Coupling of Bone Formation to Bone Resorption , 2005 .
[152] P. Delmas. Hormone replacement therapy in the prevention and treatment of osteoporosis , 2005, Osteoporosis International.
[153] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .
[154] P. Delmas,et al. Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide. , 2004, Methods in molecular medicine.
[155] P. Cloos,et al. Characterization of aged osteocalcin fragments derived from bone resorption. , 2004, Clinical laboratory.
[156] P. Sexton,et al. Molecular pharmacology of the calcitonin receptor. , 2002, Receptors & channels.
[157] G. Guyatt,et al. Meta-Analyses of Therapies for Postmenopausal Osteoporosis , 2002 .
[158] W. B. van den Berg. Lessons from animal models of arthritis. , 2002, Current rheumatology reports.
[159] G. Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. , 2002, Endocrine reviews.
[160] A. Yee,et al. Structure and function of aggrecan , 2002, Cell Research.
[161] A. Kerin,et al. Molecular basis of osteoarthritis: biomechanical aspects , 2002, Cellular and Molecular Life Sciences CMLS.
[162] B. Tang,et al. ADAMTS: a novel family of extracellular matrix proteases. , 2001, The international journal of biochemistry & cell biology.
[163] L. Lesko,et al. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.
[164] R. Moskowitz,et al. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. , 1999, Arthritis and rheumatism.
[165] L. Davis. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. , 1998, Journal of nurse-midwifery.
[166] M. Karsdal,et al. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of Salmon Calcitonin , 2008, BMC clinical pharmacology.